Regulation of EIF2B Complex in Translation Initiation (P17866)
Regulation of EIF2B Complex in Translation Initiation
Eukaryotic translation initiation factor 2B (eIF2B complex) is a protein that plays a critical role in the process of translation initiation of mRNAs in eukaryotic cells. It is composed of a complex of several subunits that are involved in the formation of the eIF2B structure and its functions in the initiation of translation. The eIF2B complex is a key regulator of the initiation of translation and its dysregulation has been implicated in various diseases, including cancer, neurodegenerative diseases, and genetic disorders.
The eIF2B complex is composed of the protein eIF2B, which is the main subunit of the complex, and several other subunits, including eIF2A, eIF2B2, eIF2B3, and eIF2B4. These subunits are held together by ionic bonds and are arranged in a specific order to form the eIF2B structure. The eIF2B structure is composed of a nucleotide-binding domain (NBD), a protein-coding domain (PCD), and a C-terminal TIR domain.
The NBD is the region of the eIF2B structure that interacts with the 26S rRNA and is involved in the formation of the NBD-26S rRNA interaction. The NBD is composed of a nucleotide-binding domain and a protein-coding domain. The protein-coding domain is responsible for the formation of the NBD-26S rRNA interaction and is composed of a unique nucleotide-binding motif (NBM) that is specific to eIF2B. The NBM is responsible for the formation of a specific interaction between the NBD and the 26S rRNA, which is essential for the initiation of translation.
The PCD is the region of the eIF2B structure that encodes the amino acid sequence of the protein. It is composed of a variable number of exons that are involved in the formation of the PCD. The C-terminal TIR domain is the region of the eIF2B structure that interacts with the factors of the translation machinery, including the factors of the 20S rRNA binding complex (RISC) and the factors of the eIF4F complex. The TIR domain is composed of a nucleotide-binding domain and a protein-coding domain.
The eIF2B complex plays a critical role in the initiation of translation initiation by interacting with the 26S rRNA and the factors of the translation machinery. It is well established that dysregulation of the eIF2B complex is involved in various diseases, including cancer, neurodegenerative diseases, and genetic disorders.
One of the key diseases associated with eIF2B complex dysfunction is cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. The eIF2B complex is involved in the regulation of cell growth and translation, which is critical for the development and progression of cancer. Therefore, dysregulation of the eIF2B complex has been implicated in the development and progression of cancer.
Another disease associated with eIF2B complex dysfunction is neurodegenerative diseases. Neurodegenerative diseases are a group of diseases that are characterized by the progressive loss of neurons and other nervous cells. The eIF2B complex is involved in the regulation of neurotransmitter synthesis and release, which is critical for the function of neurons. Therefore, dysregulation of the eIF2B complex has been implicated in the development and progression of neurodegenerative diseases.
Finally, eIF2B complex dysfunction has also been implicated in the development and progression of genetic disorders. Genetic disorders are a group of diseases that are characterized by the inheritance of abnormal genes or mutations. The eIF2B
Protein Name: Eukaryotic Translation Initiation Factor 2B
The "Eukaryotic translation initiation factor 2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Eukaryotic translation initiation factor 2B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8 | F8A1 | F8A2 | F8A3 | F9 | FA2H | FAAH | FAAH2 | FAAHP1 | FAAP100 | FAAP20
